Irinotecan (CPT-11) and Cisplatin as First-Line Chemotherapy for Advanced Ovarian Cancer

Toru Sugiyama,Michiaki Yakushiji,Toshiharu Kamura,M. Ikeda,Naohiko Umesaki,Kazuo Hasegawa,Mutsuo Ishikawa,Fumitaka Saji,M. Hiura,Takeshi Takahashi,Shinji Sato,Kazunori Ochiai,Fumitaka Kikkawa,Takeuchi S,Yasuo Ohashi,Kiichiro Noda

Irinotecan (CPT-11) and Cisplatin as First-Line Chemotherapy for Advanced Ovarian Cancer

2002

Toru Sugiyama
Michiaki Yakushiji
Toshiharu Kamura
M. Ikeda
Naohiko Umesaki
Kazuo Hasegawa
Mutsuo Ishikawa
Fumitaka Saji
M. Hiura
Takeshi Takahashi
Shinji Sato
Kazunori Ochiai
Fumitaka Kikkawa
Takeuchi S
Yasuo Ohashi
Kiichiro Noda

Objective: To evaluate the efficacy and toxicity of a combination of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in advanced ovarian cancer. Methods:

Keywords:

Immunology
Topoisomerase
Ovarian cancer
Cisplatin
Cancer
Performance status
Irinotecan
Medicine
Progressive disease
Chemotherapy
Ovary
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations